Several studies targeting CD44 isoforms in different cancer types are reviewed by Chen et al., covering the use of antibodies, peptides, aptamers, pharmacological compounds, HA-mediated drug delivery to CD44 expressing cells or HA-CD44 interaction inhibitors [95]. The gene discussed is CD44; the disease is cancer.